Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Mental or Behavioral Dysfunction > Psychotic Disorders

Psychotic Disorders

Psychotic Disorders are a group of severe mental health conditions characterized by a loss of contact with reality, hallucinations, delusions, and disorganized thinking.
These disorders can significantly impair an individual's ability to function in daily life.
Effective treatment and research are crucial for improving outcomes for those affected.
PubCompare.ai's AI-powered platform can revolutionize psychotic disorder research by helping researcheers locate the best protocols, ensure reproducibility, and identify the most effective approaches and prodcuts, streamlining the research process.

Most cited protocols related to «Psychotic Disorders»

1
Genetic Overlap of Psychiatric Disorders
Cited 167 times
We tested PRS for our primary GWAS on each GWAS cohort as a target set, using a GWAS where the target cohort was left out of the meta-analysis (Supplementary Table 2). To test genetic overlaps with other psychiatric diseases, we calculated PRS for DEPR and SCZ in our GWAS cohort BD cases 73 . In pairwise case subtype or psychosis analyses (Figure 2, Supplementary Table 13), we regressed outcome on the PRS adjusting for ancestry principal components and a cohort indicator using logistic regression, and visualized covariate-adjusted PRS in BD1 and BD2 subtypes (Figure 2). Outcome sample sizes were BD1 n=8,044, BD2 n=3,365, SAB n=977; BD1 cases with and without psychosis n= 2175 and 798 respectively, BD2 cases with and without psychosis n= 146 and 660.
Stahl E.A., Breen G., Forstner A.J., McQuillin A., Ripke S., Trubetskoy V., Mattheisen M., Wang Y., Coleman J.R., Gaspar H.A., de Leeuw C.A., Steinberg S., Whitehead Pavlides J.M., Trzaskowski M., Byrne E.M., Pers T.H., Holmans P.A., Richards A.L., Abbott L., Agerbo E., Akil H., Albani D., Alliey-Rodriguez N., Als T.D., Anjorin A., Antilla V., Awasthi S., Badner J.A., Bækvad-Hansen M., Barchas J.D., Bass N., Bauer M., Belliveau R., Bergen S.E., Bøcker Pedersen C., Bøen E., Boks M.P., Boocock J., Budde M., Bunney W., Burmeister M., Bybjerg-Grauholm J., Byerley W., Casas M., Cerrato F., Cervantes P., Chambert K., Charney A.W., Chen D., Churchhouse C., Clarke T.K., Coryell W., Craig D.W., Cruceanu C., Curtis D., Czerski P.M., Dale A.M., de Jong S., Degenhardt F., Del-Favero J., DePaulo J.R., Djurovic S., Dobbyn A.L., Dumont A., Elvsåshagen T., Escott-Price V., Chieh Fan C., Fischer S.B., Flickinger M., Foroud T.M., Forty L., Frank J., Fraser C., Freimer N.B., Frisén L., Gade K., Gage D., Garnham J., Giambartolomei C., Giørtz Pedersen M., Goldstein J., Gordon S.D., Gordon-Smith K., Green E.K., Green M.J., Greenwood T.A., Grove J., Guan W., Guzman-Parra J., Hamshere M.L., Hautzinger M., Heilbronner U., Herms S., Hipolito M., Hoffmann P., Holland D., Huckins L., Jamain S., Johnson J.S., Juréus A., Kandaswamy R., Karlsson R., Kennedy J.L., Kittel-Schneider S., Knowles J.A., Kogevinas M., Koller A.C., Kupka R., Lavebratt C., Lawrence J., Lawson W.B., Leber M., Lee P.H., Levy S.E., Li J.Z., Liu C., Lucae S., Maaser A., MacIntyre D.J., Mahon P.B., Maier W., Martinsson L., McCarroll S., McGuffin P., McInnis M.G., McKay J.D., Medeiros H., Medland S.E., Meng F., Milani L., Montgomery G.W., Morris D.W., Mühleisen T.W., Mullins N., Nguyen H., Nievergelt C.M., Nordin Adolfsson A., Nwulia E.A., ODonovan C., Olde Loohuis L.M., Ori A.P., Oruc L., Ösby U., Perlis R.H., Perry A., Pfennig A., Potash J.B., Purcell S.M., Regeer E.J., Reif A., Reinbold C.S., Rice J.P., Rivas F., Rivera M., Roussos P., Ruderfer D.M., Ryu E., Sánchez-Mora C., Schatzberg A.F., Scheftner W.A., Schork N.J., Shannon Weickert C., Shehktman T., Shilling P.D., Sigurdsson E., Slaney C., Smeland O.B., Sobell J.L., Søholm Hansen C., Spijker A.T., St Clair D., Steffens M., Strauss J.S., Streit F., Strohmaier J., Szelinger S., Thompson R.C., Thorgeirsson T.E., Treutlein J., Vedder H., Wang W., Watson S.J., Weickert T.W., Witt S.H., Xi S., Xu W., Young A.H., Zandi P., Zhang P., Zöllner S., Consortium E., Consortium B., Adolfsson R., Agartz I., Alda M., Backlund L., Baune B.T., Bellivier F., Berrettini W.H., Biernacka J.M., Blackwood D.H., Boehnke M., Børglum A.D., Corvin A., Craddock N., Daly M.J., Dannlowski U., Esko T., Etain B., Frye M., Fullerton J.M., Gershon E.S., Gill M., Goes F., Grigoroiu-Serbanescu M., Hauser J., Hougaard D.M., Hultman C.M., Jones I., Jones L.A., Kahn R.S., Kirov G., Landén M., Leboyer M., Lewis C.M., Li Q.S., Lissowska J., Martin N.G., Mayoral F., McElroy S.L., McIntosh A.M., McMahon F.J., Melle I., Metspalu A., Mitchell P.B., Morken G., Mors O., Bo Mortensen P., Müller-Myhsok B., Myers R.M., Neale B.M., Nimgaonkar V., Nordentoft M., Nöthen M.M., ODonovan M.C., Oedegaard K.J., Owen M.J., Paciga S.A., Pato C., Pato M.T., Posthuma D., Ramos-Quiroga J.A., Ribasés M., Rietschel M., Rouleau G.A., Schalling M., Schofield P.R., Schulze T.G., Serretti A., Smoller J.W., Stefansson H., Stefansson K., Stordal E., Sullivan P.F., Turecki G., Vaaler A.E., Vieta E., Vincent J.B., Werge T., Nurnberger J.I., Wray N.R., Di Florio A., Edenberg H.J., Cichon S., Ophoff R.A., Scott L.J., Andreassen O.A., Kelsoe J, & Sklar P. (2019). Genome-wide association study identifies 30 Loci Associated with Bipolar Disorder. Nature genetics, 51(5), 793-803.
Publication 2019
Genome-Wide Association Study Hereditary Diseases Psychotic Disorders
2
Genetic Overlap of Psychiatric Disorders
Cited 141 times
We tested PRS for our primary GWAS on each GWAS cohort as a target set, using a GWAS where the target cohort was left out of the meta-analysis (Supplementary Table 2). To test genetic overlaps with other psychiatric diseases, we calculated PRS for DEPR and SCZ in our GWAS cohort BD cases 73 . In pairwise case subtype or psychosis analyses (Figure 2, Supplementary Table 13), we regressed outcome on the PRS adjusting for ancestry principal components and a cohort indicator using logistic regression, and visualized covariate-adjusted PRS in BD1 and BD2 subtypes (Figure 2). Outcome sample sizes were BD1 n=8,044, BD2 n=3,365, SAB n=977; BD1 cases with and without psychosis n= 2175 and 798 respectively, BD2 cases with and without psychosis n= 146 and 660.
Stahl E.A., Breen G., Forstner A.J., McQuillin A., Ripke S., Trubetskoy V., Mattheisen M., Wang Y., Coleman J.R., Gaspar H.A., de Leeuw C.A., Steinberg S., Whitehead Pavlides J.M., Trzaskowski M., Byrne E.M., Pers T.H., Holmans P.A., Richards A.L., Abbott L., Agerbo E., Akil H., Albani D., Alliey-Rodriguez N., Als T.D., Anjorin A., Antilla V., Awasthi S., Badner J.A., Bækvad-Hansen M., Barchas J.D., Bass N., Bauer M., Belliveau R., Bergen S.E., Bøcker Pedersen C., Bøen E., Boks M.P., Boocock J., Budde M., Bunney W., Burmeister M., Bybjerg-Grauholm J., Byerley W., Casas M., Cerrato F., Cervantes P., Chambert K., Charney A.W., Chen D., Churchhouse C., Clarke T.K., Coryell W., Craig D.W., Cruceanu C., Curtis D., Czerski P.M., Dale A.M., de Jong S., Degenhardt F., Del-Favero J., DePaulo J.R., Djurovic S., Dobbyn A.L., Dumont A., Elvsåshagen T., Escott-Price V., Chieh Fan C., Fischer S.B., Flickinger M., Foroud T.M., Forty L., Frank J., Fraser C., Freimer N.B., Frisén L., Gade K., Gage D., Garnham J., Giambartolomei C., Giørtz Pedersen M., Goldstein J., Gordon S.D., Gordon-Smith K., Green E.K., Green M.J., Greenwood T.A., Grove J., Guan W., Guzman-Parra J., Hamshere M.L., Hautzinger M., Heilbronner U., Herms S., Hipolito M., Hoffmann P., Holland D., Huckins L., Jamain S., Johnson J.S., Juréus A., Kandaswamy R., Karlsson R., Kennedy J.L., Kittel-Schneider S., Knowles J.A., Kogevinas M., Koller A.C., Kupka R., Lavebratt C., Lawrence J., Lawson W.B., Leber M., Lee P.H., Levy S.E., Li J.Z., Liu C., Lucae S., Maaser A., MacIntyre D.J., Mahon P.B., Maier W., Martinsson L., McCarroll S., McGuffin P., McInnis M.G., McKay J.D., Medeiros H., Medland S.E., Meng F., Milani L., Montgomery G.W., Morris D.W., Mühleisen T.W., Mullins N., Nguyen H., Nievergelt C.M., Nordin Adolfsson A., Nwulia E.A., ODonovan C., Olde Loohuis L.M., Ori A.P., Oruc L., Ösby U., Perlis R.H., Perry A., Pfennig A., Potash J.B., Purcell S.M., Regeer E.J., Reif A., Reinbold C.S., Rice J.P., Rivas F., Rivera M., Roussos P., Ruderfer D.M., Ryu E., Sánchez-Mora C., Schatzberg A.F., Scheftner W.A., Schork N.J., Shannon Weickert C., Shehktman T., Shilling P.D., Sigurdsson E., Slaney C., Smeland O.B., Sobell J.L., Søholm Hansen C., Spijker A.T., St Clair D., Steffens M., Strauss J.S., Streit F., Strohmaier J., Szelinger S., Thompson R.C., Thorgeirsson T.E., Treutlein J., Vedder H., Wang W., Watson S.J., Weickert T.W., Witt S.H., Xi S., Xu W., Young A.H., Zandi P., Zhang P., Zöllner S., Consortium E., Consortium B., Adolfsson R., Agartz I., Alda M., Backlund L., Baune B.T., Bellivier F., Berrettini W.H., Biernacka J.M., Blackwood D.H., Boehnke M., Børglum A.D., Corvin A., Craddock N., Daly M.J., Dannlowski U., Esko T., Etain B., Frye M., Fullerton J.M., Gershon E.S., Gill M., Goes F., Grigoroiu-Serbanescu M., Hauser J., Hougaard D.M., Hultman C.M., Jones I., Jones L.A., Kahn R.S., Kirov G., Landén M., Leboyer M., Lewis C.M., Li Q.S., Lissowska J., Martin N.G., Mayoral F., McElroy S.L., McIntosh A.M., McMahon F.J., Melle I., Metspalu A., Mitchell P.B., Morken G., Mors O., Bo Mortensen P., Müller-Myhsok B., Myers R.M., Neale B.M., Nimgaonkar V., Nordentoft M., Nöthen M.M., ODonovan M.C., Oedegaard K.J., Owen M.J., Paciga S.A., Pato C., Pato M.T., Posthuma D., Ramos-Quiroga J.A., Ribasés M., Rietschel M., Rouleau G.A., Schalling M., Schofield P.R., Schulze T.G., Serretti A., Smoller J.W., Stefansson H., Stefansson K., Stordal E., Sullivan P.F., Turecki G., Vaaler A.E., Vieta E., Vincent J.B., Werge T., Nurnberger J.I., Wray N.R., Di Florio A., Edenberg H.J., Cichon S., Ophoff R.A., Scott L.J., Andreassen O.A., Kelsoe J, & Sklar P. (2019). Genome-wide association study identifies 30 Loci Associated with Bipolar Disorder. Nature genetics, 51(5), 793-803.
Publication 2019
Genome-Wide Association Study Hereditary Diseases Psychotic Disorders
3
Trauma, PTSD, and Depression in Urban Patients
Cited 65 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
African American Eligibility Determination Ethics Committees, Research Historical Trauma Intellectual Disability Pharmaceutical Preparations Post-Traumatic Stress Disorder Primary Health Care Psychotic Disorders Rooming-in Care SCID Mice Woman Wounds and Injuries
4
Developing Consensus Criteria for Treatment-Resistant Schizophrenia
Cited 64 times
An iterative approach was adopted to develop criteria for treatment resistance in schizophrenia. Initially, a systematic review of definitions of treatment resistant schizophrenia used in clinical trials was conducted. A literature search of PubMed, PsycINFO, and Embase from January 1980 to January 2016 was undertaken using the search string: “(randomized or random or randomly) and (resistant or refractory or clozapine) and (schizophrenia)”. Titles and abstracts were reviewed to initially determine eligibility. The reference lists of each relevant paper were also searched, as were reference lists of relevant review papers, to further identify potential studies. Studies were included if they were randomized controlled trials of a pharmacological intervention in adults with treatment resistant schizophrenia. Studies were excluded if they were naturalistic, or purely of biomarkers such as neuroimaging measures, studies of adjuvant treatments or non-pharmacological interventions, studies of childhood onset or late onset schizophrenia.
The data extracted were: the prerequisites for previous antipsychotic treatment (requirements of different antipsychotics, minimum treatment duration, dose); the specified severity of symptoms; and whether there was a stipulation for resistance to be prospectively demonstrated. Additionally, whether criteria were operationalized or not was recorded. To be considered as operationalized, the study had to report criteria that met the following characteristics: 1) The use of a validated rating scale to determine symptom severity; 2) A specification of minimum symptom duration; and 3) A definition of adequate treatment that specified minimum dose, duration, and number of previous antipsychotics.
Subsequently, a working group - consisting of expert researchers and clinicians, scientists from the pharmaceutical industry and other specialists with experience and expertise in the area of schizophrenia - was identified by the co-chairs of the Treatment Response and Resistance in Psychosis working group (OH, JMK, CUC). This was augmented by attendees at TRRIP meetings held at international conferences in the field. Members of the final working group included researchers who had published recently in the field and researchers who attended the inaugural TRRIP meeting at the Schizophrenia International Research Society Biennial meeting in 2014. The working group mapped out the key criteria and operationalized them.
Second, members of the TRRIP working group were contacted and invited to take part in an on-line survey to identify key areas of agreement and disagreement. The survey was developed by the TRRIP co-chairs and modified with input from TRRIP work group members. In its final version (see Appendix 1), the survey was conducted using SurveyMonkey (www.surveymonkey.com). 48 researchers and clinicians were invited by email to take part in the survey. Over the 30-day collection period, 29 responses (60%), covering 13 countries, were received to the on-line survey; 3 (10%) responses were incomplete. See supplementary information for a summary of the responses to individual items. These responses were synthesized and refined during subsequent discussions amongst the whole group to derive the consensus recommendations for both minimum and optimum criteria.
Third, the working group met to consider and revise criteria for which there was a lack of consensus. The revised criteria were circulated to the TRRIP working group members, and presented as part of an open workshop at an international meeting in the field for further discussion, input and refinement. Finally, consensus was reached regarding this publication through review by all authors.
Howes O.D., McCutcheon R., Agid O., de Bartolomeis A., van Beveren N.J., Birnbaum M.L., Bloomfield M.A., Bressan R.A., Buchanan R.W., Carpenter W.T., Castle D.J., Citrome L., Daskalakis Z.J., Davidson M., Drake R.J., Dursun S., Ebdrup B.H., Elkis H., Falkai P., Fleischacker W.W., Gadelha A., Gaughran F., Glenthøj B.Y., Graff-Guerrero A., Hallak J.E., Honer W.G., Kennedy J., Kinon B.J., Lawrie S.M., Lee J., Leweke F.M., MacCabe J.H., McNabb C.B., Meltzer H., Möller H.J., Nakajima S., Pantelis C., Reis Marques T., Remington G., Rossell S.L., Russell B.R., Siu C.O., Suzuki T., Sommer I.E., Taylor D., Thomas N., Üçok A., Umbricht D., Walters J.T., Kane J, & Correll C.U. (2016). Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. The American journal of psychiatry, 174(3), 216-229.
Publication 2016
Adult Antipsychotic Agents ARID1A protein, human Biological Markers Clozapine Conferences Eligibility Determination Pharmaceutical Adjuvants Psychotic Disorders Schizophrenia Schizophrenia, Treatment-Resistant Specialists
5
Longitudinal Study of Childhood Bipolar Disorder
Cited 60 times
The methods for COBY have been described in detail elsewhere.4 (link), 7 (link) Briefly, youth ages 7 to 17 years 11 months with Diagnostic and Statistical Manual-IV (DSM-IV) bipolar-I, II, and operationally 4 (link), 7 (link) defined bipolar-NOS were included. Youth with COBY-defined bipolar-NOS were previously shown to convert to bipolar-I/II and have a comparable, but less severe clinical picture, and similar family history, rates of comorbid disorders, and longitudinal outcome as compared to bipolar-I subjects.4 (link), 7 (link)
Youth with schizophrenia, mental retardation, autism, and mood disorders secondary to substances, medications or medical conditions were excluded.
Subjects were recruited from outpatient clinics (67.6%), inpatient units (14.3%), advertisement (13.3%), and referrals from other physicians (4.8%), and were enrolled independent of current mood state or treatment status.
The analyses presented in this report are based on the prospective evaluation of 413 subjects, including 244 (59.1%) with bipolar-I, 28 (6.8%) with bipolar-II and 141 (34.1%) with bipolar-NOS who had at least one follow-up assessment. At the time this article was written, subjects had been prospectively interviewed every 37.5±20.8 weeks for an average of 191.5 ± 75.7 weeks. Subjects with bipolar-II were followed significantly longer (227.4±76.6 weeks) than the other two bipolar subtypes (bipolar-I: 183.2±71.8 weeks, bipolar-NOS: 198.7±79.8 weeks) (F=5.4, p=.005).
As described in more detail in a prior publication, 7 (link) at intake subjects with bipolar-NOS were the youngest, followed by subjects with bipolar-I and then those with bipolar-II (Table 1). More youth with bipolar-NOS were in Tanner stage-I of sexual development than those with bipolar-II and more subjects with bipolar-II were Tanner IV/V than those with bipolar-I and -II. The mean age-of-onset for mood symptoms and DSM-IV mood episodes was 8.4 and 9.3 years, respectively (for definition of age-of-onset see below). Subjects with bipolar-II had the onset of their mood symptoms and episodes significantly later than the other two bipolar subtypes. As expected, by definition, the polarity of the index episode reflected the bipolar subtype with mania or hypomania being more common in youth with bipolar-I than those with bipolar-II or NOS. However, youth with bipolar-II had significantly more depressive index episodes that the other two bipolar subtypes. Subjects with bipolar-I had more lifetime psychosis than those with bipolar-NOS (for all above comparisons p-values <.05, Cohen’s d: 0.3–0.9). There were no other significant between group differences.
The subject retention rate at the time this manuscript was written was 86%, with 93% of subjects completing at least one follow-up interview. Except for lower rates of anxiety disorders in subjects who dropped from the study (54.5%, vs. 38.7%, p=0.02) there were no other demographic or clinical differences between the subjects who continued or withdrew from COBY.
Birmaher B., Axelson D., Goldstein B., Strober M., Gill M.K., Hunt J., Houck P., Ha W., Iyengar S., Kim E., Yen S., Hower H., Esposito C., Goldstein T., Ryan N, & Keller M. (2009). Four-Year Longitudinal Course of Children and Adolescents with Bipolar Spectrum Disorder: The Course and Outcome of Bipolar Youth (COBY) Study. The American journal of psychiatry, 166(7), 795-804.
Publication 2009
Anxiety Disorders Autistic Disorder Diagnosis Inpatient Intellectual Disability Mania Mood Mood Disorders Pharmaceutical Preparations Physicians Psychotic Disorders Retention (Psychology) Schizophrenia Sexual Development Youth

Most recents protocols related to «Psychotic Disorders»

1
Recruiting Adult Outpatients for Depression
Patients between 18 and 65 years of age referred to a treatment package for single-episode depression will be recruited (Table 1) with minimal exclusion criteria to recruit representative adult outpatients who would typically receive treatment in routine practice (Table 1), of which the majority are women (71%) and aged 18–35 (68%) (S. Figure 1). Patients over 65 (approximately 0.7% of the target population) are excluded because of potential age-related cognitive decline, concomitant medical conditions, or medications that could interact with assessments or treatment (S. Figure 1). Allocation into the subcohorts is based on eligibility, e.g., MRI compatibility, scheduling, and patient willingness to participate.

Inclusion and exclusion criteria for patients

Patient inclusion criteria:

• Fulfilment of ICD-10 diagnostic criteria for a primary depressive episode (i.e., not secondary to known organic or other psychiatric disorder)

• Referral to a treatment package for single-episode depression

• Age between 18 and 65 years

Exclusion criteria:

• Psychosis or psychotic symptoms

• History of severe head trauma involving hospitalization or unconsciousness for more than 5 min

• Known, substantial structural brain abnormalities

• Insufficient Danish language skills to complete questionnaires and cognitive testing

Additional exclusion criteria for subcohort I:

• Severe somatic disease

• Contraindications for MRI (e.g., metal implants, claustrophobia, or back problems)

Additional exclusion criteria for subcohort I:

• Use of psychotropic drugs

• Exposure to radioactivity > 10 mSv within the last year

• Pregnancy or breastfeeding

The primary depressive episode, consistent with the International Statistical Classification of Diseases and Related Health Problems version 10 (ICD-10) criteria for MDD without psychotic features (F32.1, F32.2, F32.8 and F32.9), is confirmed by a specialist in psychiatry at the central diagnostic and referral centre.
Jensen K.H., Dam V.H., Ganz M., Fisher P.M., Ip C.T., Sankar A., Marstrand-Joergensen M.R., Ozenne B., Osler M., Penninx B.W., Pinborg L.H., Frokjaer V.G., Knudsen G.M, & Jørgensen M.B. (2023). Deep phenotyping towards precision psychiatry of first-episode depression — the Brain Drugs-Depression cohort. BMC Psychiatry, 23, 151.
Full text: Click here
Publication 2023
Adult Brain Claustrophobia Cognition Congenital Abnormality Craniocerebral Trauma Diagnosis Diploid Cell Disorders, Cognitive Eligibility Determination Hospitalization Mental Disorders Metals Outpatients Patients Pharmaceutical Preparations Pregnancy Psychotic Disorders Psychotropic Drugs Radioactivity Satisfaction Target Population Woman
2
Schizophrenia Outpatients Psychiatric Evaluation
Stable outpatients under regular treatment received prior psychiatric diagnosis after a three-step procedure consisting of the following: (a) careful clinical observation with at least three evaluations; (b) a family interview; and (c) a review of their medical records performed by a trained psychiatrist. All met the following inclusion criteria: Diagnostic and Statistical Manual of Mental Disorders, DSM-5; (14 ) diagnosis of schizophrenia; aged between 18 and 65 years; under stable drug treatment adjusted to their clinical state for at least 3 months; and not involved in any other physical activity programs during the intervention. Patients were recruited from the services where they were being clinically followed (HCPA or CAPES) and were allocated to the intervention group (individuals from HCPA underwent IF, and individuals from CAPES underwent IA) (Figure 1).
The exclusion criteria were as follows: alcohol or other drug abuse in the previous month; major systemic or neurological diseases; physical disability contraindicating physical activity or any physical condition that makes physical activity unsafe; suicide risk confirmed by direct contact with the patient and family; pregnancy or women of reproductive age that did not use a contraception method; and not agreeing to participate in the study after full explanation of the program.
Controls were recruited through specific social networks (Figure 2). Then, they were paired by sex, age (3 years older or younger), and social class [we followed the classification criteria by classes of the Brazilian Institute of Geography and Statistics (IBGE), which uses the monthly income of all the residents of the same house to list from the richest to the poorest]. Thus, they were divided into the following classes: A (monthly income above R$ 20,900), B (monthly income between R$ 10,450.01 and R$ 20,900), C (monthly income above R$ 4,180 but up to R$ 10,450), D (monthly income between R$ 2,090.01 and R$ 4,180), and E (monthly income of no more than R$ 2,090).
The absence of any major mental illness was defined by a direct interview in which questions about life experiences of memory loss, psychosis (delusions and/or hallucinations), depression, mania, generalized anxiety disorder, and obsessive-compulsive symptoms were asked. Additionally, the subjects were asked about regular physical activity as they were supposed to be sedentary. Exclusion criteria were the same as those applied to patients with SCZ.
Cristiano V.B., Szortyka M.F, & Belmonte-de-Abreu P. (2023). A controlled open clinical trial of the positive effect of a physical intervention on quality of life in schizophrenia. Frontiers in Psychiatry, 14, 1066541.
Full text: Click here
Publication 2023
Anxiety Disorders Care, Ambulatory Contraceptive Methods Delusions Diagnosis Disabled Persons Drug Abuse Ethanol Hallucinations Mania Memory Loss Mental Disorders Nervous System Disorder Patients Pharmaceutical Preparations Physical Examination Pregnancy Psychiatrist Psychotic Disorders Reproduction Schizophrenia Tests, Diagnostic Woman Youth
3
Cerebral Infarction Rehabilitation Protocol
One hundred and forty patients with cerebral infarction treated in the Department of Rehabilitation Medicine of Beijing Tiantan Hospital between January 2021 and August 2022 were enrolled as a study group. Another one hundred and forty healthy people were collected as a control group. There were no significant differences in age, gender, height, or weight (Table 1). This study was approved by the ethics committee of Beijing Tiantan Hospital, Capital Medical University (KY2021-040-02).
The inclusion criteria were: (1) age 40–70 years old, (2) primary basal ganglia area cerebral infarction diagnosed by magnetic resonance imaging or computed tomography, (3) the onset of the disease was >1 month ago, (4) no sensory impairments, (5) no serious cognitive dysfunction (Mini-Mental State Examination score >26), (6) could walk 10 m or more independently, and (7) provided a signed informed consent form.
The exclusion criteria were: (1) cerebrovascular disease progression and unstable vital signs; (2) other neurological or mental diseases, such as stroke, brain trauma, or Parkinson’s disease; (3) severe heart, lung, liver, or kidney dysfunction; (4) sensory aphasia, cognitive impairment, or unable to cooperate with the evaluation and examination; (5) fractures and arthritis affecting the walking function of patients; or (6) proprioception disorders.
The suspension criteria were: (1) severe adverse reactions or inability to continue, (2) deterioration of the condition or serious complications, (3) failure to cooperate and to receive required treatment, or (4) patients and their families requesting withdrawal from the study.
Liu S., Yu H., Wang Z, & Dai P. (2023). Correlation analysis of balance function with plantar pressure distribution and gait parameters in patients with cerebral infarction in the basal ganglia region. Frontiers in Neuroscience, 17, 1099843.
Full text: Click here
Publication 2023
Arthritis Basal Ganglia Cerebral Infarction Cerebrovascular Accident Cerebrovascular Disorders Disease Progression Disorders, Cognitive Ethics Committees, Clinical Fracture, Bone Gender Heart Involuntary Treatment Kidney Failure Liver Lung Mini Mental State Examination Patients Proprioceptive Disorders Psychotic Disorders Receptive Aphasia Signs, Vital Traumatic Brain Injury X-Ray Computed Tomography
4
Longitudinal Neuroimaging of PTSD Patients
Participant recruitment for the study commenced from August 2009 and ended June 2014. Participants were 51 treatment-seeking patients, 36 of whom had viable imaging data at baseline and 27 of these with follow-up MRI data. For this manuscript we include data from the 27 PTSD patients (13 females; age = 40.9 ± 11.8 years) who completed MRIs at both visits (see CONSORT diagram in Supplementary Fig. S1).
The PTSD sample had developed PTSD after experiencing assault, childhood abuse, motor vehicle accidents, or during police duties. PTSD was diagnosed according to DSM-IV criteria by masters or doctoral level clinical psychologists using the Clinician Administered PTSD Scale (CAPS; [19 (link)]. Symptoms were detected according to the ‘2/1’ method, in which symptoms were experienced for at least twice a month and caused moderate levels of distress. Levels of depression and anxiety were assessed using the Depression, Anxiety, and Stress Scale (DASS). Patients that reported psychosis, bipolar disorder, substance dependence, neurological disorders, or moderate to severe brain injury were excluded from the study. Patients taking medication (10 on selective serotonin reuptake inhibitors) were included on the condition that the dosage was stable for the previous two months and continued to be stable for the duration of the study. In addition, 21 controls (9 females; mean age 36.9 ± 14.0 years) who were age and gender-matched to the PTSD group were included in the study. Control participants had not experienced a Criterion A stressor and did not have an Axis I disorder, as assessed by the Mini International Neuropsychiatric Interview (MINI version 5.5) [20 (link)].
All participants underwent clinical and imaging assessments at baseline and again 12 weeks later. This study was approved by the Western Sydney Area Health Service Human Research Ethics Committee and informed consent was obtained from participants.
Korgaonkar M.S., Felmingham K.L., Malhi G.S., Williamson T.H., Williams L.M, & Bryant R.A. (2023). Changes in neural responses during affective and non-affective tasks and improvement of posttraumatic stress disorder symptoms following trauma-focused psychotherapy. Translational Psychiatry, 13, 85.
Full text: Click here
Publication 2023
Anxiety Bipolar Disorder Brain Injuries Drug Abuse Epistropheus Ethics Committees, Research Females Gender Homo sapiens Magnetic Resonance Imaging Nervous System Disorder Patients Pharmaceutical Preparations Physicians Post-Traumatic Stress Disorder Psychotic Disorders Selective Serotonin Reuptake Inhibitors Substance Dependence Traffic Accidents
5
Qualitative Interviews on Adolescent Pandemic Experiences
We recruited participants nationally through social media (Facebook, Instagram, Twitter, LinkedIn, and Reddit), email campaigns, distribution of flyers, and communication with our SMEs and partnerships that our center has developed with community organizations (eg, school systems). Eligibility criteria required participants to be fluent in English, aged 14-18 years, to have access to Wi-Fi, to not be experiencing active psychosis or suicidality, and to live within the United States. Participants were restricted to the United States given that the pandemic was at different stages of quarantine and restriction worldwide and that technology access and common use may differ substantially based on culture and location. We received >200 emails from individuals who expressed an interest in participating in the interviews. However, 66 individuals were not eligible to participate based on the study criteria; most of them were ineligible because they were based outside the United States. A total of 88 individuals were lost to follow-up. A total of 50 interviews were conducted.
High school and undergraduate research interns conducted interviews with all participants. A research staff member was also on the call to provide support and input as needed. Interns were trained in semistructured interviewing techniques and followed an interview script to conduct the interview (Multimedia Appendix 1 provides a list of the interview questions). They were also trained on how to adhere to the safety protocol should adolescents disclose high-risk behavior. Interviews were scheduled for 60 minutes and were completed via Zoom. Interviewees were by themselves in their homes or at a location of their choice during the interviews, and they were compensated with an electronic gift card for their participation in the study.
Rimel S.E., Bam D., Farren L., Thaanum A., Smith A., Park S.Y., Boeldt D.L, & Nicksic Sigmon C.A. (2023). Technology Use During the COVID-19 Pandemic and the Ways in Which Technology Can Support Adolescent Well-being: Qualitative Exploratory Study. JMIR Formative Research, 7, e41694.
Full text: Click here
Publication 2023
Adolescent Eligibility Determination Pandemics Psychotic Disorders Quarantine Safety

Top products related to «Psychotic Disorders»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
3
Stata version 14 by StataCorp
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
4
Spss version 22 by IBM
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
5
Realtime hiv 1 test by Abbott
Sourced in United States, Canada
The Abbott RealTime HIV-1 test is a quantitative real-time PCR assay designed for the detection and quantification of HIV-1 RNA in human plasma samples.
6
Stata 13 by StataCorp
Sourced in United States, Denmark, United Kingdom, Austria, Sweden
Stata 13 is a comprehensive, integrated statistical software package developed by StataCorp. It provides a wide range of data management, statistical analysis, and graphical capabilities. Stata 13 is designed to handle complex data structures and offers a variety of statistical methods for researchers and analysts.
7
Spss statistics version 20 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium
SPSS Statistics version 20 is a comprehensive software package for statistical analysis. It provides a wide range of statistical procedures and techniques for data management, analysis, and presentation. The software is designed to handle a variety of data types and can be used for tasks such as descriptive statistics, regression analysis, and hypothesis testing.
8
Spss version 25 by IBM
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
9
Spss version 20 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Spain, France, Denmark, Switzerland, Ireland
SPSS version 20 is a statistical software package developed by IBM. It provides a range of data analysis and management tools. The core function of SPSS version 20 is to assist users in conducting statistical analysis on data.
10
Spss version 23 by IBM
Sourced in United States, United Kingdom, Japan, Austria, Germany, Belgium, Israel, Hong Kong, India
SPSS version 23 is a statistical software package developed by IBM. It provides tools for data analysis, data management, and data visualization. The core function of SPSS is to assist users in analyzing and interpreting data through various statistical techniques.

More about "Psychotic Disorders"

Psychotic disorders are a group of severe mental health conditions that involve a detachment from reality.
These disorders, which include schizophrenia, schizoaffective disorder, and delusional disorder, are characterized by hallucinations, delusions, disorganized thinking, and impaired functioning.
Effective treatment and research are critical for improving outcomes for those affected.
PubCompare.ai, an AI-powered platform, can revolutionize psychotic disorder research by helping researchers locate the best protocols, ensure reproducibility, and identify the most effective approaches and products.
This can streamline the research process and accelerate progress in understanding and treating these complex conditions.
Researchers can use PubCompare.ai to access a comprehensive database of literature, pre-prints, and patents related to psychotic disorders.
The platform's intelligent comparison capabilities can help identify the most promising protocols and interventions, ensuring that studies are designed with the highest standards of reproducibility and accuracy.
In addition to locating the best research protocols, PubCompare.ai can also assist researchers in analyzing their data.
The platform integrates with popular statistical software like SAS version 9.4, Stata version 14, and SPSS version 22.0, allowing researchers to seamlessly incorporate their findings into their research workflow.
Furthermore, PubCompare.ai can help researchers stay up-to-date with the latest developments in psychotic disorder research, including the emergence of new diagnostic tools like the Abbott RealTime HIV-1 test and advancements in statistical software like Stata 13 and SPSS version 23.
By harnessing the power of AI and data analysis, PubCompare.ai can empower researchers to make groundbreaking discoveries in the field of psychotic disorders, ultimately improving the lives of those affected by these debilitating conditions.
One typo: 'prodcuts' should be 'products'.